ARO-ALK7
NCT06937203
Arrowhead · Phase 1/2 · Recruiting · Enrollment 150
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Part 1 and Part 2 (optional cohort): ARO-ALK7 | n/r | n/r | n/r | n/r | n/r |
| Part 1 and Part 2 (optional cohort): Placebo | n/r | n/r | n/r | n/r | n/r |
| Part:2: ARO-ALK7 + Tirzepatide | n/r | n/r | n/r | n/r | n/r |
| Part 2: Placebo + Tirzepatide | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.